After a delay, the Alpha-3 study faces an April futility analysis.
ApexOnco Front Page
Recent articles
A first-in-human trial of PRT12396 starts next month.
Early data are coming with the KRAS G12D degrader ARV-806.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
